Novel immunoassay detecting p-Tau Thr217 distinguishes Alzheimer’s Disease from other dementias

Jozef Hanes, Andrej Kovac, Hlin Kvartsberg, Eva Kontsekova, Lubica Fialova, Stanislav Katina, Branislav Kovacech, Eva Stevens, Jakub Hort, Martin Vyhnalek, Lynn Boonkamp, Michal Novak, Henrik Zetterberg, Oskar Hansson, Philip Scheltens, Kaj Blennow, Charlotte E. Teunissen & Norbert Zilka
Objective To investigate whether p-tau T217 assay in cerebrospinal fluid (CSF) can distinguishes Alzheimer’s disease from other dementias and healthy controls. Methods We developed and validated a novel Simoa immunoassay to detect p-tau T217 in CSF. There was a total of 190 participants from three cohorts with AD (n = 77) and other neurodegenerative diseases (n = 69) as well as healthy subjects (n = 44). Results The p-tau T217 assay (cut-off 242 pg/ml) identified...
1 citation reported since publication in 2020.
79 views reported since publication in 2020.

These counts follow the COUNTER Code of Practice, meaning that Internet robots and repeats within a certain time frame are excluded.
What does this mean?
19 downloads reported since publication in 2020.

These counts follow the COUNTER Code of Practice, meaning that Internet robots and repeats within a certain time frame are excluded.
What does this mean?